Demystifying spirometry at the point of care
/0 Comments/in COPD, MedCitizens, Medical Devices, spirometry, SYN, Top Story /by CAPTISPeptiDream and J&J ink billion-dollar drug discovery deal
/0 Comments/in Biotech, Daily, j&j, Janssen, Japan, New Jersey, PeptideDream, Pharma, SYN, Top Story /by CAPTISA look at the evolution of the user interface in healthcare
/0 Comments/in Daily, doctors, Health IT, MedCitizens, Patient Engagement, SYN, Top Story /by CAPTIS74 percent of physicians believe communication improves when patients set the agenda
/0 Comments/in Daily, EHR, EMR, Health IT, MedCity News eNewsletter, Patient, Patient Engagement, physician, Seattle, Seattle Washington, SYN, Top Story /by CAPTISFDA allows 23andMe to reintroduce 10 genetic health risk reports for Parkinson’s, Alzheimer’s, and more
/0 Comments/in 23andMe, alzheimer's disease, Biotech, California, Diagnostics, Medical Devices, Mountain View, Parkinson's Disease, SYN, Top Story /by CAPTISRepublicans are stuck on healthcare but they have no choice but to persevere
/0 Comments/in ACA, Daily, Health Policy, healthcare reform, Kaiser, MedCity News eNewsletter, Obamacare, Politics, SYN, Top Story /by CAPTISVA uses predictive analytics to prevent suicides, contemplates scrapping VistA EHR
/0 Comments/in Daily, David Shulkin, department of veterans affairs, EHR, Health IT, MedCity News eNewsletter, Politics, SYN, Top Story, U.S. Department of Veterans Affairs, VA, veterans, VistA /by CAPTISThe expanding ecosystem of microbiome startups
/0 Comments/in Azitra, Biotech, Connecticut, Convergence, Daily, Finch Therapeutics, Massachsuetts, microbiome, Pharma, Startups, SYN, Takeda Pharmaceuticals, Top Story, ulcerative colitis /by CAPTISMore funding and another powerful pharma backer have entered the microbiome space, showing that at least some investors and pharma execs believe the field can begin converting preclinical ideas into valid human therapies.
Somerville, Massachusetts-based Finch Therapeutics announced a new agreement with Takeda Pharmaceuticals on Wednesday, a solid endorsement of its sophisticated bioinformatics platform.
Along with oncology and central nervous system disorders, gastrointestinal diseases are one of Takeda’s three therapeutic pillars. As part of the deal, Takeda will pay an upfront $10 million for exclusive worldwide rights to FIN-524, an investigational drug for ulcerative colitis, and any follow-on products for irritable bowel diseases (IBDs). Ulcerative colitis is a form of IBD in which the immune system attacks the lining of the large intestine.
Finch’s science taps into the high-potential, highly-unpalatable concept of a fecal transplant. It involves transferring a microbiota rich stool sample from a healthy individual into someone with severe gut dysbiosis.
It’s a smart approach, given how little we know about the many thousands of microbial strains that occupy our guts. Instead of adding them to a therapy one-by-one, scientists can take a sample ecosystem that is already known to work. Finch then has a feedback loop in place to determine how patients responded to the different donor cultures.
“By working from clinically annotated datasets of donor and patient microbiota before and after fecal transplantation, we can look for the patterns in changes to the patients’ microbiota associated with targeted clinical outcomes,” said Finch CEO Mark Smith in an email forwarded by a company representative.
It underscores how variable our microbiomes are, whether we’re healthy, sick, or somewhere in between.
Smith cited a 70-patient randomized control trial of fecal transplants performed at McMaster University (Moayyedi et al, 2015). Five donors were used in the study, but just one, Donor B, had a demonstrably large therapeutic effect. Without Donor B, the study would have failed.
Just how much Kombucha was Donor B drinking? And how do we learn from the strength of that participant’s microbiota? Finch is working to answer the latter.
While gut bacteria and the microbiome are often used interchangeably, our microscopic citizens really populate our entire body, including the skin. That’s the target for Farmington, Connecticut-based Azitra.
Azitra announced on Wednesday that it had closed a $2.9 million Series A venture round led by Bios Partners. With earlier seed funding, including from Peter Thiel’s Breakout Labs program, the startup has raised $3.75 million to date.
Rather than brewing a complex bacterial concoction, Azitra has identified one key bacteria strain for its lead candidate, AZT-01, to be applied as a cream to affected skin. In its cross-hairs for treatment are eczema, rare genetic skin diseases, and more everyday cosmetic applications such as dry skin.
In an email forwarded by a company representative, Azitra Cofounder and CSO Travis Whitfill said the microbial treatment isn’t just a band-aid — it could address an underlying cause.
“Studies have repeatedly shown that these patients have an imbalanced microbiome, and in the case of eczema, they often have an overgrowth of Staph aureus. There is also evidence that our strain of bacteria can kill some strains of Staph aureus, which is one of the reasons we chose it as a chassis,” Whitfill said.
Applied topically, the good bacteria can colonize the area and begin correcting the dysbiosis.
Photo: spawns, Getty Images
Intermountain Healthcare Innovation Fund gives some more love to Redox
/0 Comments/in Chicago, Daily, Health IT, Healthbox, Hospitals, Illinois, Intermountain Healthcare Innovation Fund, Madison, Newsletter, Redox, Salt Lake City, Startups, SYN, Top Story, Utah, Wisconsin /by CAPTISRedox Engine, the Madison, Wisconsin health IT startup that’s helping healthcare facilities overcome interoperability challenges has received $1 million in follow-on investment from Intermountain Healthcare Innovation Fund, according to a company release. The funding is part of Redox’s Series B round.
Redox will work with Intermountain in the Salt Lake City-based health system’s push to adopt digital health solutions that fit into their electronic health record. The company will also support applications Intermountain has developed, such as the Rehab Outcomes Management System, as part of Redox’s API platform.
Healthbox has previously run an accelerator for healthcare startups called Healthbox Studio but with the management change last year, Healthbox repositioned itself as a venture capital investment manager with an innovation platform that functions as a consultant to and collaborator with healthcare partners.
Healthbox has managed Intermountain Healthcare’s Innovation Fund since the fund’s launch in 2015. The fund is intended to source, evaluate, and invest in companies that align with Intermountain’s mission. So far the fund has made a handful of investments in healthcare startups, in addition to Redox:
Zebra Medical Vision, an Israel-based health IT business, developed a clinical decision support teaching computers to read and diagnose medical images through machine learning. Last year, Zebra closed a Series B round as it launched a consumer-facing product called Profound. The service allows individuals to upload their medical imaging scans such as computerized tomography scans and mammograms to Zebra Medical Vision’s online service, and receive an automated analysis of key clinical conditions.
Syapse is a precision medicine software meets clinical decision support startup. It seeks to improve care coordination for hospitals by extracting clinical, genomic and other molecular data from medical records, labs and pharmacies and integrating that data to offer more detailed patient profiles. By doing this, the company wants to guide doctors to find the right diagnostic test and therapeutic approach. The Intermountain fund took part in its Series C round.
The fund also invested in Utah-based genomics software developer Tute Genomics, which was later acquired by PierianDx. PierianDx seeks to enable personalized medicine for clinical labs.
Photo: jpa1999, Getty Images
Archives
Follow CAPTIS
We Recommend
Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News
CAPTIS Newsletter
Call CAPTIS
United States Offices
1 (800) 445-1839
(United States & Canada Toll Free) Europe & International
+41 22 518 2100